🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Deirdre Jill Cohen

Mount Sinai Hospital

ORCID: 0000-0002-6178-9266

Also affiliated with Icahn School of Medicine at Mount Sinai

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)”.

Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae114
N/A
0.443DataRank · unranked
10 citations

Paul J. Catalano, Michelle Weitz, Edith Mitchell, Deirdre Jill Cohen, Peter J O’Dwyer +9 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps158
N/A
0.241DataRank · unranked
4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps232
N/A
0.241DataRank · unranked
4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps260
N/A
0.241DataRank · unranked
4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3647
N/A
0DataRank · unranked
4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps258
N/A
0DataRank · unranked
1 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first line therapy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4042
N/A
0DataRank · unranked
0 citations

Jonathan W. Lee, Daniel Becker, Despina Siolas, Nina Beri, Theresa Ryan +7 more

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3618
N/A
0DataRank · unranked
7 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more